Abstract
Background Long-term use of extracorporeal membrane oxygenation (ECMO) remains limited because of poor biocompatibility, which often leads to clot formation and device failure. Despite this common pathway to failure, there are no published studies on the rate of clot formation and resulting performance deficits in current oxygenators.
Methods ECMO cases with either Maquet’s CardioHelp (CH, n=28) or Quadrox (Qx, n=14) oxygenators were evaluated over a three-month period. Data was collected prospectively and included patient characteristics and hematological data. The inlet-outlet oxygen content difference (ΔCO2) and blood flow resistance were calculated as measures of device function, and device failure due to clot formation was defined as a resistance increase greater than 1 mmHg/(L/min)/day for more than one day.
Results There were no statistically significant differences in patient age, total days on ECMO, platelet count (PLT) prior to ECMO, activated partial thromboplastin time during ECMO, initial resistance, and device blood flow rate. During ECMO, the Qx group had a significantly greater change in PLT (Qx: - 34±10%; CH: 7±15%), rapidity to failure due to clot formation, and a greater decline in ΔCO2 (all p<0.05). Clot burden was focused at the center of the CH oxygenator, farthest from all inlets, whereas Qx devices developed a more diffuse clot pattern.
Conclusions Qx oxygenators clot earlier than CH oxygenators with a correlated drop in ΔCO2 and greater PLT reduction. These differences are likely due to the distributed, four-inlet CH design vs. the single inlet Qx design and differences in pump-induced platelet activation.
Competing Interest Statement
Keith Cook and Matthew Bacchetta are both co-owners of Advanced Respiratory Technologies, a company that develops products for respiratory support.
Funding Statement
This work was supported by NIH grants 2R01HL089043 and R01HL089456 and The Richard Bartlett Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by Columbia Universities IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available upon request.
